Boutas Ioannis, Kontogeorgi Adamantia, Koufopoulos Nektarios, Dimitrakakis Constantine, Dimas Dionysios, Kalantaridou Sophia N, Korou Laskarina-Maria, Perrea Despoina
Laboratory of Experimental Surgery and Surgical Research "N.S. Christeas", Athens Medical School, Athens, Greece.
Third Department of Obstetrics and Gynecology, Attikon University Hospital, Medical School of the National and Kapodistrian University of Athens, Chaidari, Greece.
Cancer Diagn Progn. 2022 Nov 3;2(6):720-730. doi: 10.21873/cdp.10167. eCollection 2022 Nov-Dec.
BACKGROUND/AIM: Utilizing an experimental animal model, we investigated the correlation between aromatase inhibitors (AIs) (anastrozole and letrozole) and Calprotectin levels. AIs have demonstrated superior efficacy when used as adjuvant endocrine therapy or monotherapy for postmenopausal patients with hormone receptor (HR)-positive early-stage breast cancer, although various side effects have been recorded.
Fifty-five adult female Wistar rats were randomized and assigned into four groups. The control group received no intervention. The other three groups were subjected to ovariectomy, and serum Calprotectin levels were measured at baseline, 2, and 4 months. In addition, glucose, total cholesterol, very low-density lipoprotein- (VLDL-) cholesterol, low-density lipoprotein (LDL-) cholesterol, high-density lipoprotein- (HDL-) cholesterol, and triglyceride levels were measured. Histological analysis of liver tissue was carried out following rats' euthanasia.
Aromatase inhibitors (anastrozole and letrozole) affect calprotectin levels in ovariectomized rats. Calprotectin, a marker of inflammation, was found to be affected by the use of the inhibitors.
The potential of hepatotoxicity can be examined by assessing the elevation of inflammation markers such as Calprotectin, which is an indicator that should be strictly taken into consideration when administering aromatase inhibitors as treatment.
背景/目的：利用实验动物模型，我们研究了芳香化酶抑制剂（AIs）（阿那曲唑和来曲唑）与钙卫蛋白水平之间的相关性。尽管已记录到各种副作用，但AIs作为绝经后激素受体（HR）阳性早期乳腺癌患者的辅助内分泌治疗或单一疗法时，已显示出卓越的疗效。
55只成年雌性Wistar大鼠被随机分为四组。对照组未接受干预。其他三组接受卵巢切除术，并在基线、2个月和4个月时测量血清钙卫蛋白水平。此外，还测量了葡萄糖、总胆固醇、极低密度脂蛋白（VLDL）胆固醇、低密度脂蛋白（LDL）胆固醇、高密度脂蛋白（HDL）胆固醇和甘油三酯水平。在大鼠安乐死后对肝脏组织进行组织学分析。
芳香化酶抑制剂（阿那曲唑和来曲唑）会影响去卵巢大鼠的钙卫蛋白水平。钙卫蛋白作为一种炎症标志物，被发现会受到抑制剂使用的影响。
可以通过评估炎症标志物如钙卫蛋白的升高来检测肝毒性的可能性，在使用芳香化酶抑制剂进行治疗时，这是一个应严格考虑的指标。
